News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck Sharp & Dohme (MRK): New EASL Data Shows Investigational Medicine 'Victrelis' (boceprevir) Gives Significantly Higher Cure Rates When Added to Peginterferon Alfa-2a and Ribavirin in Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control


4/1/2011 8:18:03 AM

BERLIN--(BUSINESS WIRE)--MSD reported that final results from a Phase III study of 'Victrelis'™ (boceprevir), its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a ('Pegasys'®) marketed by Roche Products Limited, and ribavirin therapy (PR) were presented for the first time today as part of a late-breaker poster session at The International Liver Congress™ / 46th European Association for the Study of the Liver (EASL) annual meeting.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES